Beijing Sun-Novo Pharmaceutical Research Co., Ltd. (SHA:688621)
China · Delayed Price · Currency is CNY 61.96
+0.86 (1.41%)
Mar 20, 2026, 11:29 AM CST
SHA:688621 Revenue
In the year 2025, Beijing Sun-Novo Pharmaceutical Research had annual revenue of 1.22B CNY with 12.92% growth. Beijing Sun-Novo Pharmaceutical Research had revenue of 362.05M in the quarter ending December 31, 2025, with 123.77% growth.
Revenue
1.22B
Revenue Growth
+12.92%
P/S Ratio
5.48
Revenue / Employee
782.66K
Employees
1,359
Market Cap
6.68B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 1.22B | 139.34M | 12.92% |
| Dec 31, 2024 | 1.08B | 146.35M | 15.70% |
| Dec 31, 2023 | 932.12M | 255.51M | 37.76% |
| Dec 31, 2022 | 676.61M | 182.96M | 37.06% |
| Dec 31, 2021 | 493.65M | 146.29M | 42.12% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Guizhou Bailing Group Pharmaceutical | 3.15B |
| Hunan Jiudian Pharmaceutical | 3.05B |
| Jiangsu Lianhuan Pharmaceutical | 2.60B |
| Sunflower Pharmaceutical Group Co.,Ltd | 2.09B |
| Heilongjiang ZBD Pharmaceutical | 1.59B |
| Shanghai Kaibao Pharmaceutical CO.,Ltd | 1.17B |
| Sichuan Huiyu Pharmaceutical | 998.15M |
| Hainan Haiyao | 825.66M |